Sign in

You're signed outSign in or to get full access.

Lital Barda

Chief Financial Officer at N2OFF
Executive

About Lital Barda

Lital Barda (age 38) is Chief Financial Officer of N2OFF, Inc. (ticker NITO) since April 2022; she holds a B.A. in accounting from Ono Academic College and is a certified public accountant in Israel, with concurrent experience providing accounting/controlling services to public and private companies . The company’s filings describe her role and regulatory certifications (SOX 302 and 906) in Q3 2025, evidencing responsibility for disclosure controls and financial reporting integrity . The proxy and filings do not disclose TSR- or revenue/EBITDA-linked performance targets for her pay; compensation is reported as salary, cash bonus, and stock awards, with no outstanding equity awards at FY2024 and no options tied to explicit performance metrics .

Past Roles

OrganizationRoleYearsStrategic Impact
N2OFF, Inc.Chief Financial OfficerApr 2022–presentPrincipal financial and accounting officer; oversight of disclosure controls and financial reporting (SOX certifications)
Not disclosed

External Roles

OrganizationRoleYearsStrategic Impact
Shlomo Zakai, CPAAccountant and Financial ControllerNov 2017–presentProvides accounting/controlling services to public/private companies

Fixed Compensation

Metric20232024
Salary (USD)$60,976 $84,122
Cash Bonus (USD)$7,500 $7,500

Consulting agreement cash terms:

  • Base monthly fee: NIS 25,000; agreement may be terminated by either party on 30 days’ written notice .
  • Amendment: 15% cash compensation increase as of November 10, 2024 .

Performance Compensation

Equity awards (restricted stock; no options outstanding at FY2024):

Award TypeGrant DateSharesFair Value / PriceVesting
Restricted Common StockMar 29, 2023409$165.97 per share (total $67,943) Not disclosed
Restricted Common StockDec 30, 2023817$62.825 per share (total $51,142) Not disclosed
Restricted Common StockSep 12, 20244,572$9.45 per share (total $43,920) Not disclosed
Common Stock (under 2022 Plan)May 12, 2025300,000Issued under Plan; price not disclosed Not disclosed

Notes:

  • Outstanding equity awards at FY2024: none (no options/RSUs outstanding as of year-end) .
  • Plan mechanics: the 2022 Share Incentive Plan allows the administrator to accelerate vesting or cash-out awards in change-of-control or similar transactions; detailed single/double-trigger terms are not specified in the proxy summary .

Equity Ownership & Alignment

HolderShares Beneficially Owned% of Outstanding
Lital Barda14,370<1%
  • Anti-hedging: Company policy prohibits hedging/monetization transactions for directors, officers, employees, consultants, and contractors, reinforcing alignment with shareholder outcomes .
  • Pledging: No explicit pledging disclosure found; insider trading policy and anti-hedging are referenced but pledging is not specifically addressed in the proxy text provided .
  • Stock ownership guidelines: Not disclosed in the proxy text provided .

Employment Terms

TermDetail
EngagementConsulting agreement between Save Foods Ltd. (operating subsidiary) and Shlomo Zakai CPA for CFO services provided exclusively by Lital Barda
Base CompensationNIS 25,000 per month; increased by 15% effective Nov 10, 2024
TerminationEither party may terminate with 30 days’ written notice; additional termination events per agreement
ClawbackCompany adopted a clawback policy November 12, 2023; filed as Exhibit 97.1 to Annual Report on Form 10-K
Change-of-Control (Plan)2022 Plan permits administrator to assume/substitute awards, accelerate vesting, or cash-out awards in mergers, consolidations, asset sales, or relevant transactions; specific triggers/multiples not detailed in proxy summary

Risk Indicators & Red Flags

  • Section 16(a) reporting: Company disclosed a late Form 4 for Ms. Barda, who failed to timely report issuance of 160,000 shares under the 2022 Plan; this indicates control/reporting process risk and potential governance scrutiny .
  • Large share issuance (May 12, 2025): 300,000 shares issued under the 2022 Plan to the CFO could create overhang and potential future selling pressure depending on vesting and lock-up terms, which were not disclosed in the 8-K .
  • Anti-hedging policy in place; no explicit anti-pledging disclosure observed in proxy text provided .

Compensation Committee Analysis

  • Composition: Compensation committee consists of independent directors Ronen Rosenbloom, Israel Berenstein, and Eliahou Arbib; Israel Berenstein is chair; members meet Nasdaq heightened independence standards and Rule 16b-3 “non-employee director” definition .
  • Activity: One meeting and four unanimous written consents in FY2024; responsible for CEO/other executive compensation, director compensation, and oversight of compensation consultants .

Say-on-Pay & Shareholder Feedback

  • Not disclosed in the proxy text provided; proposals in 2025 proxy include plan share increase and advisory vote on director grants, but historical say-on-pay outcomes are not presented .

Investment Implications

  • Pay-for-performance alignment is limited: Ms. Barda’s compensation is primarily salary, modest cash bonus, and restricted stock; the proxy does not disclose performance-based metrics or PSU structures for her role, and FY2024 shows no outstanding equity awards, reducing ongoing performance linkage .
  • Ownership/skin-in-the-game is small (<1%): Beneficial ownership of 14,370 shares suggests low direct economic exposure; however, substantial grants (300,000 shares in May 2025) could materially change exposure depending on vesting and retention terms; these terms were not disclosed, creating uncertainty on alignment and potential overhang .
  • Governance/process risk: A late Form 4 for a large equity issuance (160,000 shares) highlights reporting control weaknesses; investors should monitor Section 16 compliance and future insider activity closely .
  • Protections and flexibility: The company has an anti-hedging policy and a clawback policy, but the 2022 Plan provides broad administrative discretion on vesting changes in change-of-control scenarios rather than explicit single/double triggers, which may be investor-unfriendly relative to best-practice transparency .
Key actions: monitor subsequent filings for vesting, lock-up, or resale registration details on 2025 grants; track Section 16 compliance and any insider sales; assess dilution dynamics from plan share increases and board director grants relative to fully diluted share count.